Citations 12
Challenges posed by COVID‐19 in cancer patients: A narrative review
Afshar, Zeinab Mohseni , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil , Alijanpour, Amirmasoud , Hosseinzadeh, Dariush , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Mohseni Afshar, Zeinab , Sayad, Babak , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Babazadeh, Arefeh , Barary, Mohammad , Alijanpour, Amirmasoud , Miri, Seyed Rouhollah
Cancer Medicine | December 24, 2021 | Volume: 11 | Issue: 4 | Pages: 1119-1135
AbstractA novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early 2020, the World Health Organization declared COVID‐19 the sixth public health emergency of international concern. The COVID‐19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID‐19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID‐19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID‐19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.
Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities
Afshar, Zeinab Mohseni , Janbakhsh, Alireza , Mansouri, Feizollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Janbakhsh, Alireza , Mansouri, Feizollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil
Reviews in Medical Virology | October 22, 2021 | Volume: 32 | Issue: 3 | Pages: No page available
SummaryVaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.